Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9712382 | 0.90 | RAB9A (0.48) | ALDH1A1LMNAMAPTNPC1MAPK1 | |
| SCHEMBL4376001 | 0.90 | POLB (0.49) | LMNAMAPTNPC1MAPK1HTT | |
| SCHEMBL9490579 | 0.88 | MAPT (0.53) | ALDH1A1LMNAMAPTNPC1MAPK1 | |
| SCHEMBL9712546 | 0.87 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTHTTAKR1C3 | |
| SCHEMBL8471201 | 0.85 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTNPC1MAPK1 | |
| SCHEMBL8012007 | 0.85 | POLB (0.55) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL7673359 | 0.82 | AKR1C3 (0.61) | ALDH1A1LMNAMAPTNPC1AKR1C3 | |
| SCHEMBL6462550 | 0.78 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTNPC1MAPK1 | |
| SCHEMBL9782367 | 0.77 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTNPC1MAPK1 | |
| SCHEMBL14995290 | 0.76 | MAPT (0.50) | ALDH1A1LMNAMAPTNPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156771-B2 | Process for the preparation of enolate salts of 4-fluoro-2-hydroxymethylene-3 oxo-butyrates | LONZA LTD (CH) | 2015-10-13 | — | — | US | disclosed |
| US-20130338394-A1 | PROCESS FOR THE PREPARATION OF ENOLATE SALTS OF 4-FLUORO-2-HYDROXYMETHYLENE-3 OXO-BUTYRATES | LONZA LTD. (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-2593420-A1 | PROCESS FOR THE PREPARATION OF ENOLATE SALTS OF 4-FLUORO-2-HYDROXYMETHYLENE-3-OXO-BUTYRATES | Lonza Ltd (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007142-A1 | PROCESS FOR THE PREPARATION OF ENOLATE SALTS OF 4-FLUORO-2-HYDROXYMETHYLENE-3-OXO-BUTYRATES | LONZA LTD (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338394-A1 | PROCESS FOR THE PREPARATION OF ENOLATE SALTS OF 4-FLUORO-2-HYDROXYMETHYLENE-3 OXO-BUTYRATES | ELOVL3, ELOVL1, EEF1B2 | ALDH1A1 341/4885LMNA 2023/4885MAPT 3183/4885 |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | CUTA, GLRA3, ARGLU1 | ALDH1A1 4073/4885LMNA 2447/4885MAPT 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.